key: cord-0689327-6evzh44r
authors: Orsó, Evelyn; Werner, Tobias; Wolf, Zsuzsanna; Bandulik, Sascha; Kramer, Werner; Schmitz, Gerd
title: Ezetimib influences the expression of raft‐associated antigens in human monocytes
date: 2006-02-14
journal: Cytometry A
DOI: 10.1002/cyto.a.20229
sha: a661f6b3d9770e4f00f5c37a35bd23196d2810d6
doc_id: 689327
cord_uid: 6evzh44r

Aminopeptidase N (CD13) was recently identified as a molecular target of the cholesterol absorption inhibitor Ezetimib. Regarding that CD13 is expressed in lipid rafts of monocytic cells, we have investigated whether Ezetimib influences raft function in these cells. Expression of raft‐associated antigens (CD11b, CD13, CD14, CD16, CD36, and CD64) was followed by flow cytometry and/or immunoblot in human monocyte‐derived macrophages in response to in vitro administration of Ezetimib. Cellular redistribution of CD13 was assessed by confocal imaging. Ezetimib significantly decreased the surface expression of CD13, CD16, CD64, and CD36; furthermore, it induced a shift of CD13 from plasma membrane to intracellular vesicles, and thus it quite likely modulated monocytic raft‐assembly. © 2006 International Society for Analytical Cytology

Aminopeptidase N (CD13) is a transmembrane ectoenzyme of zinc metalloproteases with a broad expression in cells/tissues, including myeloid cells, hepatocytes, various epithelial cells, nervous system, and placenta (1) . CD13 is involved in certain biological processes, such as growth and invasion of tumors, cellular motility, regulation of angiogenesis, cellular internalization of human coronavirus 229E, and modulation of the effect of IL-6 or IL-8, neuropeptides, and chemotactic peptides [1-3 and references therein]. More recently, CD13 has been implicated as a molecular target of Ezetimib, an azetidinonetype cholesterol absorption inhibitor and plasma cholesterol lowering drug, in enterocytic brush border membrane (4) .

CD13 is a raft microdomain-resident, type II membrane protein, and both of its homodimeric polypeptides have a very short cytoplasmic domain of eight amino acid residues with no described signaling motifs (2, 3) . Thus, it is tempting to speculate that signal transduction through CD13 requires additional membrane proteins, quite likely localized in rafts. In a recent study, Mina-Osorio and Ortega provide evidence that CD13 functionally interacts with the Fcg receptor I (CD64) on monocytic cells (3) . As characterized by fluorescence resonance energy transfer (FRET), human monocytes contain a CD14, CD32, CD64, CD47, and CD55-containing, raft-associated, constitutive receptor cluster (5) . Activation of monocytes by lipopolysaccharide (LPS) or lipoteichoic acid leads to coassembly of CD14, CD32, CD64, CD55, CD11b/CD18, CD16, CD81, CD36, and the toll-like receptor-4 (TLR4), but not CD47 in these rafts (5) .

Since Ezetimib binds to CD13, and CD13 quite likely interacts with other receptor(s) in raft microdomains, we have investigated whether Ezetimib influences the assembly of monocyte rafts or the expression of raft-associated antigens or both.

Monocytes of healthy volunteers were isolated by leukapheresis followed by counterflow elutriation after informed consent. Cells were cultured in serum-free macrophage medium (SFM; Gibco/Invitrogen, Karlsruhe, Germany) containing 50 ng/ml recombinant human macrophage-colony stimulating factor (M-CSF; R&D Systems, Wiesbaden, Germany), with or without supplementation of 10 lM Ezetimib ((3R,4S)-1-(4-fluorphenyl)-3-[(3S)-3-(4-fluorphenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-on (Aventis Pharma, Frankfurt am Main, Germany), up to 5 days. The percentage of damaged (i.e., apoptotic or necrotic) cells as determined by propidium iodide exclusion was <20% irrespective of treatment. 

Detergent lysis with 1% Lubrol WX (Serva, Heidelberg, Germany) and sucrose gradient flotation was carried out as described previously (6) . Immunoblotting of cellular fractions or whole cell lysates was performed as described earlier (5), using the CD13 mAb (3D8, Santa Cruz Biotechnology, Heidelberg, Germany). 

Cells were cultured on sodium borosilicate coverglasses (Nunc, Wiesbaden, Germany), fixed with 4% paraformaldehyde (Polysciences, Eppelheim, Germany), permeabilized by 0.25% Triton X-100 (Sigma-Aldrich) and labeled according to standard procedures. In addition to the CD13-FITC staining, plasma membrane was also visualized by mouse antihuman annexin II IgG1 (clone 5, BD Biosciences), and Texas Red-conjugated horse anti-mouse IgG (Vector Laboratories/Alexis, Gruenberg, Germany). Confocal images were taken by a TCS 4D inverted confocal laser scanning microscope (Leica Lasertechnik, Bensheim, Germany), and analyzed by the MetaMorph 6.2 software package (Universal Imaging, Glendale, WI).

Ezetimib significantly decreases the surface expression of CD13, CD16, CD64, and CD36 of monocyte-derived macrophages, but has no marked effect on the surface expression of CD14 and CD11b (Fig. 1A) .

To explore whether the decreased surface expression of CD13 is related to a cellular internalization of CD13, the cellular distribution of CD13 in Ezetimib-treated cells was investigated by confocal imaging. In control cells, a substantial part of CD13-fluorescence is detected at the cell surface showing extensive colocalization with the plasma membrane marker annexin II. By contrast, in Ezetimib-treated cells, the major colocalization of CD13 and annexin II occurs in cytoplasmic vesicles, and thus Ezetimib quite likely induces a redistribution of CD13 or annexin II or both from the plasma membrane to intracellular vesicles (Fig. 1B) .

Lysis of cells in 1% Lubrol WX followed by sucrose flotation gradient-separation confirms the presence of CD13 in detergent resistant membranes (DRMs) (i.e. rafts) in control cells, whereas CD13 is elicited in detergent soluble (i.e. non-raft) fractions in response to Ezetimib (Fig. 1C) .

Parallel to the marked changes in cellular CD13 redistribution, Ezetimib also decreases the total cellular content of CD13 (Fig. 1D) .

Ezetimib is a lipid-lowering drug, which inhibits intestinal cholesterol absorption by an unknown cellular mechanism that requires binding of Ezetimib to CD13 in the enterocytic brush border (4). The binding site for Ezetimib on CD13 differs from the aminopeptidase activity of this antigen (4). Since CD13 is constitutively expressed in lipid rafts of monocytes/macrophages, it is tempting to speculate that Ezetimib influences structure and/or function of rafts in these cells. Indeed, the present study provides evidence that Ezetimib modulates the cellular redistribution and expression of CD13 in monocyte-derived macrophages. Moreover, the expression of further raftassociated antigens such as the Fcg receptors CD16 and CD64, and the scavenger receptor CD36, extensively implicated in cellular uptake of modified lipoproteins or phagocytosis, is also down-regulated in response to Ezetimib. The decreased expression of these receptors upon Ezetimib administration may lead to an impaired macrophage-differentiation and lipid-uptake, and thus Ezetimib quite likely exerts an in vitro antiatherogenic effect in monocyte-derived macrophages, which involves rafts.

CD13 requires ''co-receptor(s)'' for subsequent signaling, and CD64, CD16, or CD36 are demonstrated or are putative CD13-interacting antigens (3) . Ezetimib may exert its cellular effect through disruption of the coassembly of CD13 with CD64/CD16 or CD36, and in this scenario, the missing coassociation of receptors may lead to their disappearance from rafts. The finding that CD13 disappears from DRMs/rafts in response to Ezetimib (Fig. 1C ) may support this hypothesis. Binding of Ezetimib to CD13 quite likely induces a conformational change in the extracellular domain of CD13, masking the specific sequence required for coassociation of CD13 with other receptors. Such a mechanism has recently been proposed for Ezetimib in enterocytes (4) . Alternatively, shedding of CD13 in response to Ezetimib may also explain the loss of its expression.

In summary, Ezetimib likely modifies raft assembly in monocyte-derived macrophages through a CD13-dependent dissociation of preclustered receptor complexes.

Structure and expression of aminopeptidase N

Aminopeptidase N/CD13 is associated with raft membrane microdomains in monocytes

Aminopeptidase N (CD13) functionally interacts with FcgRs in human monocytes

Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor Ezetimibe in the enterocyte brush border membrane

Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts

Apo AI/ABCA1-dependent and HDL3-mediated lipid efflux from compositionally distinct cholesterol-based microdomains